Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 291 participants.
Also called NCT02226003
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 291 participants
- Sponsor
- Registry
-
NCT02226003 -
2014-001049-25
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT02226003. Randomized; double masking; primary purpose treatment. Start 2014-09-23 (actual); primary completion 2016-02-23 (actual). Results posted on 2017-04-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Ertugliflozin
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo to Ertugliflozin
- Intervention (Drug)
- Placebo to Sitagliptin
- Intervention (Drug)
- Glimepiride
- Lead sponsor
- Merck Sharp & Dohme LLC
- Collaborator
- Pfizer
Record details
- Record id
cardio:ct-nct02226003- Content hash
2fe9e550d64165a49e317fcb4c4032c46ab03e92384b4e28695265aa416be4dc